The study also demonstrated that Levemir provides good glycaemic control in both types of diabetes and reduced rates of hypoglycaemia.
Type I diabetes patients treated with Levemir gained significantly less weight than those on NPH insulin and also had significantly improved glycaemic control.
According to the company, benefits of Levemir have been further confirmed in the large randomized clinical trial predictive 303, involving more than 5,000 patients. Type II diabetes patients who were switched from NPH insulin or insulin glargine to Levemir over a period of 26 weeks actually lost weight, while still experiencing significant improvements in glycaemic control and reduced rates of hypoglycemia.
Professor Luigi Meneghini, associate director at the diabetes research institute, University of Miami Miller School of Medicine, commented: “The fact that Levemir provides better glycaemic control, less nocturnal hypoglycaemia and less weight gain relative to NPH insulin over a period of two years is a clinical confirmation of the superior action profile of Levemir.”